Nolato AB (publ) (NOLA_B) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, and welcome to today's presentation with Nolato. With us presenting today, we have the CEO, Christer Wahlqvist, and CFO, Per-Olo Holmström. If you're calling in and would like to ask a question, please press star 9 to raise your hand, and star 6 to unmute yourself when you get the word. You can also submit written questions using the form to the right. And with that said, please go ahead with your presentation. Good afternoon and welcome to the presentation of Nolato's third quarter 2025. This is Krister Walkie speaking. During the quarter we saw organic growth in both our two business areas, approximately 2% if we adjust for currency, and that in combination with a strong increase of our margins created a strong increase of our EBITDA. So the sales ended up at 2.3 billion and some, and the operating profit rose 20% to 281. That includes a non-recurring item of 7 million corresponding to an insurance claim. But as I mentioned, we saw strong improvements of margins in both business areas. We have maintained a very strong financial position with a debt ratio of 0.6 times EBITDA, giving us opportunity and possibility to expand together with the right business cases from existing and new customers, as well as executing on our acquisition strategies. The Nolato Group consists of two business areas, the medical solution being the largest part at approximately 56% of group sales and engineered a little bit less than 50% and the rest of the business. Starting out with medical solutions. Here we see sustainable growth and global expansions. And on this graph, you will see a 20-year show of our sales over the last 20 years. So we've seen good growth over the years. We have a very spread business with six focus product areas, and there are also well-spread sales...